Dossier assessment
Olopatadine/mometasone (allergic rhinitis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Olopatadine/mometasone (allergic rhinitis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Olopatadine/mometasone (allergic rhinitis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-06-01 A G-BA decision was published.
Project details
- Project no.
- A22-125
- Commission
- Commission awarded on 29.11.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Olopatadine/mometasone furoate (allergic rhinitis) – Addendum to Commission A22-125
Status: Commission completed